Results 171 to 180 of about 8,846,713 (318)
Accumulative index of published articles in profile vol. 16 (2014) [PDF]
Journal, PROFILE
core
Senator Millen tells the Labor senators what he thinks of them [picture] /
Title from inscription below image.; Percy Deane Collection.; Reproduced in Caricatures by Low ...
Low, David, 1891-1963.
core
Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis +3 more
wiley +1 more source
Artists Keith Harrison and LOW PROFILE visited the Harris for an insight into their works, ‘Conductor’, and ‘PEOPLE’
Harrison, K
core
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
Diagnostic and Prognostic Implications of Ultra-Low-Profile INCRAFT and Ovation Endografts: Long-Term Follow-Up in a Single-Center Experience. [PDF]
Oddi FM +8 more
europepmc +1 more source
Finding novel vulnerabilities of hypomorphic BRCA1 alleles
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder +10 more
wiley +1 more source
A Low-Profile Self-Stealth Programmable Metasurface with In-Band and Out-of-Band RCS Reduction. [PDF]
Mu Y +6 more
europepmc +1 more source
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi +14 more
wiley +1 more source

